Clinical trials: Breast Cancer, Metastatic
PIK3CA Mutation, Solid Tumor, Adult
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor…
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
- Trial name
- NCT05216432
- Testing
- RLY-2608, Fulvestrant, Palbociclib 125mg
- Where
- 37 sites in United States, Australia and 3 more
- Volunteers
- 930 people
- Sponsor
- Relay Therapeutics, Inc.
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.
- Trial name
- NCT05021900
- Testing
- Tenalisib 800mg, Tenalisib 1200mg
- Where
- 3 sites in Georgia
- Volunteers
- 40 people
- Sponsor
- Rhizen Pharmaceuticals SA
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
Breast Cancer Proteomics and Molecular Heterogeneity
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor…
- Trial name
- NCT01840293
- Where
- 6 sites in Ireland
- Volunteers
- 1,780 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of weekly paclitaxel plus bevacizumab as first line treatment in elderly patients (≥ 70 years old) with metastatic breast cancer.
- Trial name
- NCT01120158
- Testing
- Bevacizumab, Paclitaxel
- Where
- 11 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer, HER2-positive Breast Cancer
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I
- Trial name
- NCT05036252
- Testing
- Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms, Metastases, Neoplasm
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the…
- Trial name
- NCT00037609
- Testing
- Capecitabine, Exisulind
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Estrogen Receptor-Positive Breast Cancer
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
- Trial name
- ENCORE301 (NCT00676663)
- Testing
- entinostat, exemestane
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 130 people
- Sponsor
- Syndax Pharmaceuticals
Metastatic Breast Cancer
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast…
- Trial name
- NCT00370552
- Testing
- Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 136 people
- Sponsor
- R-Pharm
Metastatic Breast Cancer, Metastatic Prostate Cancer
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers.
- Trial name
- NCT07252726
- Testing
- Morning administration of CDK4/6 inhibitor, Evening administration of CDK4/6 inhibitor, Morning administration of ARPI
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer
This study will investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic or recurrent breast cancer.
- Trial name
- NCT00226928
- Testing
- Supportive-Expressive Group Therapy plus education, Education
- Volunteers
- 125 people
- Sponsor
- Stanford University
Bone Pain, Breast Carcinoma Metastatic in the Bone
Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone
This trial studies histamine and bone pain association in participants with breast cancer that has spread to the bone. Studying histamine levels in samples of blood from participants with breast cancer in the laboratory may help…
- Trial name
- NCT03529565
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Survivors Uniting for Remote Guided Exercise
The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among…
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior
- Trial name
- SURGE (NCT07290309)
- Testing
- Virtually Supervised Exercise Sessions, Asynchronous Group
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Colorado State University
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Central Nervous System Neoplasms, Neoplasm Metastasis
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts.
- Trial name
- CN-306 (NCT00629187)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tufts Medical Center
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer, Gemcitabine
Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer
The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease…
- Conditions
- Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer, Gemcitabine, Maintenance Chemotherapy
- Trial name
- NCT02188693
- Where
- China
- Volunteers
- 267 people
- Sponsor
- Xijing Hospital
Breast Cancer
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005649
- Testing
- capecitabine, paclitaxel
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HER2 Positive Breast Cancer
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together.
- Trial name
- HER2CLIMB-04 (NCT04539938)
- Testing
- tucatinib, trastuzumab deruxtecan
- Where
- 140 sites in United States
- Volunteers
- 70 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00003638
- Testing
- Detox-B adjuvant, THERATOPE STn-KLH vaccine, keyhole limpet hemocyanin
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- Oncothyreon Canada Inc.
Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone…
- Trial name
- NCT04895358
- Testing
- pembrolizumab, paclitaxel, nab-paclitaxel
- Where
- 256 sites in United States, Argentina and 29 more
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Late Effects, Testicular Germ Cell Tumor Mixed
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments.
- Conditions
- Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC
- Trial name
- PASCA (NCT04671693)
- Testing
- PASCA intervention
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Leon Berard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.